Cargando…

CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma

Sorafenib is the first-line drug used for patients with advanced hepatocellular carcinoma (HCC). However, acquired sorafenib resistance in cancer patients limits its efficacy. Here, we performed the first genome-wide CRISPR/Cas9-based screening on sorafenib-treated HCC cells to identify essential ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Adi, Chevalier, Nadja, Calderoni, Margot, Dubuis, Gilles, Dormond, Olivier, Ziros, Panos G., Sykiotis, Gerasimos P., Widmann, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925031/ https://www.ncbi.nlm.nih.gov/pubmed/31903165 http://dx.doi.org/10.18632/oncotarget.27361

Ejemplares similares

A Bibliometric Review of the Keap1/Nrf2 Pathway and its Related Antioxidant Compounds
por: Paunkov, Ana, et al.
Publicado: (2019)

The Keap1/Nrf2 Signaling Pathway in the Thyroid—2020 Update
por: Thanas, Christina, et al.
Publicado: (2020)

Patent Review (2017–2020) of the Keap1/Nrf2 Pathway Using PatSeer Pro: Focus on Autoimmune Diseases
por: Chartoumpekis, Dionysios V., et al.
Publicado: (2020)

Keap1/Nrf2 Signaling: A New Player in Thyroid Pathophysiology and Thyroid Cancer
por: Renaud, Cedric O., et al.
Publicado: (2019)

SAT-455 Mouse Thyroid Responds to Iodine Overload by Transcriptionally Enhancing the Keap1/Nrf2 Antioxidant Response and by Upregulating Nrf2-Dependent and Independent Inflammatory and Fibrosis Pathways
por: Chartoumpekis, Dionysios V, et al.
Publicado: (2020)

Keap1/Nrf2 Signaling Pathway
por: Sykiotis, Gerasimos P.
Publicado: (2021)

Mice Hypomorphic for Keap1, a Negative Regulator of the Nrf2 Antioxidant Response, Show Age-Dependent Diffuse Goiter with Elevated Thyrotropin Levels
por: Ziros, Panos G., et al.
Publicado: (2021)

Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study
por: Renaud, Cédric O., et al.
Publicado: (2022)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
por: Xu, Yongkang, et al.
Publicado: (2023)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
por: Xu, Yongkang, et al.
Publicado: (2022)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
por: Kim, Soo Young, et al.
Publicado: (2018)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
por: Cui, Yanjun, et al.
Publicado: (2022)

Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
por: Lu, Yonggang, et al.
Publicado: (2021)

Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity
por: Yoshioka, Naoki, et al.
Publicado: (2019)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Correction: Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
por: Lu, Yonggang, et al.
Publicado: (2022)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Nrf2 Represses FGF21 During Long-Term High-Fat Diet–Induced Obesity in Mice
por: Chartoumpekis, Dionysios V., et al.
Publicado: (2011)

OR28-01 Constitutive Activation of NRF2 Antioxidant Response Leads to Age-Dependent Goiter and Compensated Hypothyroidism in Male Mice
por: Chartoumpekis, Dionysios, et al.
Publicado: (2020)

ASIC1a affects hypothalamic signaling and regulates the daily rhythm of body temperature in mice
por: Peng, Zhong, et al.
Publicado: (2023)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Hepatic Gene Expression Profiling in Nrf2 Knockout Mice after Long-Term High-Fat Diet-Induced Obesity
por: Chartoumpekis, Dionysios V., et al.
Publicado: (2013)

Hepatic Fgf21 Expression Is Repressed after Simvastatin Treatment in Mice
por: Ziros, Panos, et al.
Publicado: (2016)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines
por: Sasaki, Reina, et al.
Publicado: (2020)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2018)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib
por: Nix, Ryan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qomjq8m16r1morb7avbhco3vmn